<DOC>
	<DOC>NCT00612495</DOC>
	<brief_summary>To determine the efficacy (response rate [RR], time to progression and survival) of oxaliplatin as a single agent and oxaliplatin in combination with 5 FU in patients with advanced/metastatic endometrial cancer pretreated with one prior chemotherapy regimen containing cisplatin (CDDP) or carboplatin and to define the safety profile of each arm of the above mentioned regimens in these patients</brief_summary>
	<brief_title>Endometrial Cancer - LOHP Alone and With 5FU</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients aged at least 18 years, with locally advanced, recurrent or metastatic endometrial adenocarcinoma, histologically diagnosed; at least 1 bidimensionally measurable lesion (&gt; or =to 2 cm on computed tomography [CT]/magnetic resonance imaging [MRI] or &gt; or =to 1 cm clinical lymph node confirmed by ultrasound or &gt; or =to 1 cm skin lesion confirmed by photograph with ruler) located in a nonirradiated area measured less than 2 weeks before inclusion, according to the National Cancer Institute Common Toxicity Criteria (NCICTC). Patients previously treated for locally advanced/metastatic disease with chemoradiotherapy (total CDDP dose &gt; or =to 100 mg/m2) or chemotherapy containing CDDP or carboplatin with at least 4 weeks' washout period from discontinuation of prior chemotherapy and fully recovered from toxic effects of prior chemotherapy (except for symptomatic peripheral neuropathy &lt; or =to NCICTC grade 1 or alopecia). Patients with clinically or radiologically documented PD or recurrence during or after last chemotherapy and hormone therapy (hormone therapy stopped before study entry), Eastern Cooperative Oncology Group performance status (ECOG PS) &lt; or =to 2, life expectancy &gt; or =to 3 months, adequate bone marrow reserve, normal renal and liver function (neutrophil count &gt; or =to 2000/mm³; platelet count &gt; or =to 100 000/mm³; creatinine levels &lt; or =to 1.5 x the upper limit of normal [ULN] of institutional values or creatinine clearance &gt; 60 mL/min; total bilirubin level &lt; 1.5 x ULN; [alanine amino transferase/aspartate aminotransferase &lt; 2.5 x ULN without liver metastases, &lt; 5 x ULN with liver metastases]). Laboratory values obtained in the week preceding study entry. Signed informed consent (prior to all study procedures)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>